Savara

Savara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for rare respiratory diseases. The company's lead product candidate, MOLBREEVI (molgramostim inhalation solution), is an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). This rare lung disease is characterized by the abnormal build-up of surfactant in the alveoli, causing impaired gas transfer and symptoms such as shortness of breath, cough, and fatigue.

Headquartered in Langhorne, Pennsylvania, Savara is working to address significant unmet medical needs in the rare respiratory disease space. The company's management team brings significant experience in orphan drug development, pulmonary medicine, and effectively advancing product candidates through clinical development to approval and commercialization. MOLBREEVI has received multiple regulatory designations including Fast Track and Breakthrough Therapy Designations from the FDA, Orphan Drug Designation from both the FDA and European Medicines Agency, and Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA.